ImmunityBio Presents Long-Term Overall Survival Data In Non-Small Cell Lung Cancer Patients And Announces Registrational Intent Phase 3 Trials With ANKTIVA And Checkpoint Immunotherapy At World Conference On Lung Cancer
ImmunityBio Presents Long-Term Overall Survival Data In Non-Small Cell Lung Cancer Patients And Announces Registrational Intent Phase 3 Trials With ANKTIVA And Checkpoint Immunotherapy At World Conference On Lung Cancer
- Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)
- ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months
- Long-term survival was independent of PDL1 tumor status and independent of 2nd or 3rd line of therapy
- The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in patients with advanced cancers
- Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1st and 2nd line NSCLC (ResQ301 and ResQ302) versus standard of care
- 在世界肺癌大會上公佈的2期數據顯示，使用KEYTRUDA（pembrolizumab）和OPDIVO（nivolumab）等檢查點抑制劑後進展的二線和三線非小細胞肺癌患者的中位總存活率延長了14個月以上
- ANKTIVA 加上 KEYTRUDA 或 OPDIVO 挽救了這些使用相同檢查點抑制劑進展的患者 t 細胞活性，12 個月時總存活率爲 57%
- 長期存活率與 PDL1 腫瘤狀態無關，與第二或第三線治療無關
- 這些數據繼續驗證了ANKTIVA在激活Nk、CD8殺手和記憶T細胞方面的作用機制，從而延長了晚期癌症患者的總體存活率
- 數據支持全球啓動針對一線和二線非小細胞肺癌（reSq301和reSq302）與標準護理的ANKTIVA和KEYTRUDA或OPDIVO的ResQ三期隨機對照試驗
Immunotherapy innovator ImmunityBio, Inc. ((IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer (NSCLC) being treated with checkpoint inhibitors (CPI). An oral presentation of the data was presented by John Wrangle, M.D., MPH, Associate Professor, Medical University of South Carolina, at the World Congress on Lung Cancer in San Diego on Sunday, September 8 in the session titled "Novel Immunotherapy Strategies and Combinations."
免疫療法創新者ImmunityBio, Inc.（IBRX）今天宣佈了其Quilt 3.055試驗的積極結果，該試驗表明，接受檢查點抑制劑（CPI）治療的晚期非小細胞肺癌（NSCLC）患者的長期存活期可延長14個月至多五年。9月8日星期日，在聖地亞哥舉行的世界肺癌大會上，南卡羅來納醫科大學副教授John Wranglewand.D.，MPH，在名爲 「新型免疫療法策略和組合」 的會議上口頭介紹了這些數據。
The phase 2b study of ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with checkpoint inhibitors KEYTRUDA or OPDIVO in multiple tumor types including NSCLC who failed CPI showed long-term overall survival of 57 percent (49/86) and 34 percent (29/86) at 12 and 18 months respectively, exceeding the current standard of care.
對ANKTIVA（nogapendekin alfa inbakicept-pmln）與檢查點抑制劑KEYTRUDA或OPDIVO聯合對包括CPI失敗的非小細胞肺癌在內的多種腫瘤類型的20期研究顯示，12個月和18個月的長期總存活率分別爲57％（49/86）和34％（29/86），超過了目前的護理標準。
譯文內容由第三人軟體翻譯。
